| Message: | SR9009 has great promise in increased exercise capacity and endurance. This compound acts as an agonist of Rev-erbα. SR9009 binds to one of the body’s natural molecules called Rev-erbα, which influences lipid and glucose metabolism in the liver, the production of fat-storing cells and the response of macrophages (cells that remove dying or dead cells) during inflammation. Current studies show activation of Rev-erbα with SR9009 led to increased metabolic activity in skeletal muscle in both culture and in mice. The treated mice had a 50 percent increase in running capacity, measured by both time and distance.
Easy to dose oral compound that boosts metabolic activity in current studies
SR9009 latches onto Rev-erbα -- which plays a role in regulating the body's circadian rhythm and metabolism -- resulting in a pronounced metabolic boost in test subjects.
Research may lead to new approaches to helping people with conditions that acutely limit exercise tolerance
SR9009 affects the primary biological clock, which coordinates the rhythm of the body’s activity with the 24-hour phase of day and night.
Recent research show that activation of Rev-erbα with SR9009 resulted to enhanced metabolic activity in skeletal muscle tissue in both culture and in mice. The authors of this new research propose that Rev-erbα affects muscle cells by stimulating both the formation of new mitochondria (more known as the “power plants” of the cell) and the authorization of those mitochondria that are flawed.
If the effects of SR9009 on mice can securely be duplicated for people, the new drug may provide new treatments for obesity and its companions, metabolic syndrome and diabetes. Another area in which SR9009 or a similar drug may present significant benefit is to balance the loss of overall muscle conditioning which transpires as a side effect of reduced activity due to sickness or old age.
|
my account
